Search for: "Par Pharmaceutical, Inc." Results 1 - 20 of 170
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
9 May 2017, 9:59 pm by Patent Docs
The decision arose out of a patent dispute between Plaintiffs Par Pharmaceutical, Inc., Par Sterile Products, LLC,... [read post]
3 Dec 2014, 9:59 pm by Patent Docs
Noonan -- That it is more difficult today to be a patentee able to defend her patent rights than any time since the 1940's is nicely illustrated by the Federal Circuit's decision in Par Pharmaceutical, Inc. v. [read post]
13 Sep 2012, 9:59 pm by Patent Docs
Par Pharmaceutical, Inc., thereby allowing Santarus to keep Par's generic version of Zegerid® off the market until the expiration of the Orange Book-listed patents. [read post]
29 Nov 2020, 9:59 pm by Patent Docs
This truism was the basis for the Federal Circuit affirming the District Court's decision against a generic drug producer in its recent decision in Par Pharmaceutical, Inc. v. [read post]
7 Jun 2010, 9:59 pm by Patent Docs
Par Pharmaceutical, Inc., the Federal Circuit exercised its prerogative to illustrate its fractured jurisprudence on two issues, obviousness and inequitable conduct, in a (fortunately) nonprecedential decision. [read post]
2 Apr 2013, 2:48 pm by Fraud Fighters
Last month, Par Pharmaceutical Companies Inc. pleaded guilty to federal criminal charges and agreed to settle civil allegations involving the company’s promotion of the drug Megace ES. [read post]
23 Jul 2007, 9:13 pm
By Sherri Oslick -- Ortho-McNeil, Inc. announced late last week that it has settled its lawsuit against Par Pharmaceutical Companies, Inc. and its subsidiaries, Par Pharmaceutical, Inc. and Kali Laboratories, Inc., over the patent covering Ortho's Ultracet ® (tramadol hydrochloride and acetaminophen, used to treat acute pain). [read post]
18 Aug 2022, 11:39 am by Eileen McDermott
’s abbreviated new drug application (ANDA) does not infringe two patents owned by Par Pharmaceutical, Inc., Par Sterile Products, LLC, and Endo Par Innovation Company, LLC (collectively, Par). [read post]
18 Aug 2022, 11:39 am by Eileen McDermott
’s abbreviated new drug application (ANDA) does not infringe two patents owned by Par Pharmaceutical, Inc., Par Sterile Products, LLC, and Endo Par Innovation Company, LLC (collectively, Par). [read post]
2 Apr 2013, 1:55 pm by fraudfighters
Last month, Par Pharmaceutical Companies Inc. pleaded guilty to federal criminal charges and agreed to settle civil allegations involving the company’s promotion of the drug Megace ES. [read post]
11 Sep 2012, 5:30 am by Gene Quinn
Par Pharmaceutical, Inc., which dealt with whether a drug covered by an Abbreviated New Drug Application (ANDA) infringed the patents owned by that patent owner relative to the proton pump inhibitors (PPI) product omeprazole. [read post]
7 Sep 2011, 4:05 pm by mcarzima@imediainc.com
A qui tam complaint against Par Pharmaceuticals was unsealed yesterday in Chicago. [read post]
5 Sep 2011, 9:36 pm by Patent Docs
Par Pharmaceutical, Inc. et al. v. [read post]
5 Sep 2012, 5:51 pm by Mandour & Associates
IPNews® - The Federal Circuit on Tuesday partially reversed a lower court's finding that a number of Santarus Inc.'s patent claims for its heartburn drug Zegerid are invalid, giving Santarus another crack at hanging Par Pharmaceuticals Inc. out to dry for trying to market a generic version of the drug. [read post]
6 Feb 2011, 9:34 pm by Patent Docs
• Defendants: Par Pharmaceutical Inc.; Par Pharmaceutical Companies Inc. [read post]
5 Mar 2013, 1:56 am by Ben Vernia
On March 5, the Department of Justice announced that generic drug maker Par Pharmaceuticals, Inc., entered a guilty plea and agreed to pay a combined $45 million to settle criminal and civil charges that it promoted Megace ES off-label. [read post]